CytomX Therapeutics (CTMX) EPS (Weighted Average and Diluted) (2019 - 2025)
CytomX Therapeutics (CTMX) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.14 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 333.33% year-over-year to -$0.14, compared with a TTM value of $0.3 through Sep 2025, up 76.47%, and an annual FY2024 reading of $0.38, up 3900.0% over the prior year.
- EPS (Weighted Average and Diluted) was -$0.14 for Q3 2025 at CytomX Therapeutics, down from -$0.06 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $0.27 in Q1 2025 and bottomed at -$0.54 in Q4 2021.
- Average EPS (Weighted Average and Diluted) over 5 years is -$0.14, with a median of -$0.08 recorded in 2024.
- The sharpest move saw EPS (Weighted Average and Diluted) soared 1050.0% in 2024, then plummeted 333.33% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.54 in 2021, then surged by 76.05% to -$0.13 in 2022, then surged by 115.38% to $0.02 in 2023, then skyrocketed by 1050.0% to $0.23 in 2024, then tumbled by 160.87% to -$0.14 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for CTMX at -$0.14 in Q3 2025, -$0.06 in Q2 2025, and $0.27 in Q1 2025.